On Monday, June 20, 2016, from 9:30 a.m. to noon US EDT, the Blood Products Advisory Committee (BPAC) met by teleconference to hear updates of research programs in the Laboratory of Plasma Derivatives (LPD) in the Division of Hematology Research and Review (DHRR), which is under the Office of Blood Research and Review (OBRR) at the FDA Center for Biologics Evaluation and Research (CBER). At noon, the Committee entered into a closed session discussion about site visit reports for OBRR research programs. The discussion influences FDA staffing decisions, and therefore it is closed because public disclosure of the reports would constitute a “clearly unwarranted invasion of personal privacy” under 5 U.S.C. 552b(c)(6).
See the SAC Tracker report